TrkB agonists, in addition to BDNF stabilizing agents, and other agent classes are insistingly reported to prospectively augment therapeutic outcomes of dopamine replacement in PD, and AAV delivery of BDNF to potentially augment amyloid-clearing mechanisms in the treatment of Alzheimer’s disease. This evidence concerns the gene BDNF and Parkinson disease.